VEGFA and breast carcinoma: Interestingly, there was experimental evidence that the combination of two anti-angiogenic molecules targeting VEGF (Bevacizumab) and its receptor (Vatalanib) reduced skeletal lesions in a mouse model of breast cancer bone metastasis, while either treatment alone had no inhibitory effect [9].